Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Level 3 contingent consideration liabilities by Quarter
Level 3 contingent consideration liabilities ($M) ($M)
Gilead Sciences Level 3 contingent consideration liabilities: $60M in Q2 2026, down 77.9% from a year earlier.
Where the Q2 2026 figure comes from
“|| Contingent consideration liability | $ | — | $ | — | $ | 60 | $ | 60 | $ | — | $ | — | $ | 278 | $ | 278”
Source: Form 10-Q (gild-20260630.htm, filed 2026-08-06) ↗
Reported in Form 10-Q / 10-K Note 3 Fair Value Measurements.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up level 3 contingent consideration liabilities
Cite this data
StockData. (2026). Gilead Sciences Level 3 contingent consideration liabilities ($M), quarterly Q1 2014–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/cc-liab-tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.